Connect with us

Legal & Regulation

President Trump Administration, FDA Seek More Public Feedback on Global Marijuana Reclassification

Published

on

President Trump Administration, FDA Seek More Public Feedback on Global Marijuana Reclassification
  • The public comment period would last for 30 days.
  • Rescheduling cannabis would not make the substance globally legal.

The legalization of marijuana in the United States is still federally illegal, though there have been many states to implement their own policies on the substance. While the Food and Drug Administration (FDA) has solicited the public’s feedback on the way that marijuana is classified in international treaties in the past, the authority is now soliciting the same data.

According to a Federal Register notice on Wednesday, the agency will be reopening the comment period, which will last for 30 days. By reopening the comment period, the public will have a new chance to change the US’s response to the drug scheduling review that is currently being pursued with United Nations (UN).

The World Health Organization stated this year that marijuana and THC should be rescheduled. As it stands, these substances are controlled by the strictest drug category involved in the international treaties. Furthermore, the UN’s WHO has also said that CBD shouldn’t have any of its current restrictions, saying that CBD “has no potential for abuse and no potential to produce dependence.”

The FDA has first asked for public input in March this year. At the time, the FDA said that they recognized the need to hold

“a shortened time period for the submission of comments to ensure that the U.S. Department of Health and Human Services may in timely fashion carry out the required action and be responsive to the United Nations.”

When the proposal was initially created in March, there was an assumption that there was a vote planned on cannabis-related recommendations with the Commission on Narcotic Drugs. However, the panel ultimately chose to postpone this action. If that happens, then the comment period would reopen. The new notice on receiving public input should be published by Thursday, when the public can submit both electronic and written comments for 30 days.

Changing cannabis’s scheduling would not make it possible for member countries to legalize it without adhering strictly to compliance protocols. However, the implementation of new scheduling for cannabis would should how the world’s most influential government organization is starting to understand this plant. Despite the UN taking a restrictive approach to cannabis, both Canada and Uruguay have been working to end prohibition.

A Supreme Court ruling in Mexico stated that prohibition of cannabis is unconstitutional, suggesting that the country will be added to the small list of regions that has legalized marijuana.

Lorraine H started her young writing career in local news journalism as a reporter many ages ago and was a refreshing insight to her opportunity of authoring engaging and helpful to the people in her community of today. While she has a Bachelor’s Degree in Media Studies And Communication, that story chasing thrill has translated into how she conducts and carries her words to the TOC community and all of her contributions.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.